Well JAV received 'approximately $12 million in upfront cash payments, and up to $59.5 million in sales and regulatory milestones. Additionally, Javelin will earn a double digit royalty on future net sales of Dyloject' in all countries included by the agreement.
The U.S. market is 4x's larger and Dyloject works better and faster than it's competition.
I'm not going to throw a number out but we either see a sale of the company or some kind of upcoming offering as the company doesn't have the funds to market/produce Dyloject. My bet is on sale of the company.



LinkBack URL
About LinkBacks
Reply With Quote

